---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005420"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:24:11.970253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks

## Summary
- In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).
- NEK7 degradation ~80-90% in T cells across all dose levels (5-400 mg); favorable safety with mild/moderate AEs, no dose dependency.
- Median IL-6 dropped 55% to below cardiovascular risk threshold; CSF IL-6 decreased 75% in two subjects, suggesting CNS effect.
- Plan to initiate Phase 2 GFORCE-2 study in ASCVD in 2026; expand GFORCE-1 with readout H2 2026.
- Also evaluating Phase 2 studies in MASH, gout, recurrent pericarditis; collaborator Novartis to initiate Phase 2 studies of MRT-6160 in 2026.

## SEC filing metadata
- accession: 0001193125-26-005420
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/0001193125-26-005420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/glue-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005420
- JSON: https://secwatch.observer/filing/0001193125-26-005420.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.